BioSpace News Archive

Primus Aerospace—a leading contract manufacturing partner to aerospace, defense & space OEMs—has joined the VELO3D partner network with the purchase of a Ti6Al4V Sapphire® metal additive manufacturing (AM) system.

Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today that the company has received clearance from the U.S. Food and Drug Administration (FDA) for a Phase 1 clinical study of MV-014-212, the company’s intranasal live attenuated chimeric vaccine candidate against SARS-CoV-2, the coronavirus that causes COVID-19.

XORTX Therapeutics Inc., a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces its participation in the Zoom with LD Mirco to be held virtually on March 18, 2021.

Packaging Technology Group, Inc (PTG), a leading provider of thermal packaging solutions for the biopharmaceutical and life sciences sector, announced today the addition of an extra-small shipper to its TRUEtemp Naturals® Line

4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, has extended its existing partnership with the University of Leeds in the UK through 2027, the two organizations announced today.

Hospital for Special Surgery announced it has received a transformative $35 million contribution from the Anna-Maria and Stephen Kellen Foundation for the construction of a state-of-the-art medical tower.

McKesson, Vanderbilt Health Rx Solutions to leverage collective expertise to advance the mission of health system specialty pharmacies

The U.S. response to the COVID-19 pandemic has failed at every level, resulting in hundreds of thousands of needless deaths, according to an article in the spring issue of the Journal of American Physicians and Surgeons.

Sector financing reached $19.9B in 2020, doubling from the previous year; 2021 is likely to be a record year for the number of regulatory decisions on new regenerative medicine products

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will participate in the Oppenheimer 31st Annual Healthcare Conference